CDXS vs. SMTI, IMMP, AKBA, EDAP, SENS, JYNT, VMD, DSGN, GLUE, and AXGN
Should you be buying Codexis stock or one of its competitors? The main competitors of Codexis include Sanara MedTech (SMTI), Immutep (IMMP), Akebia Therapeutics (AKBA), Edap Tms (EDAP), Senseonics (SENS), Joint (JYNT), Viemed Healthcare (VMD), Design Therapeutics (DSGN), Monte Rosa Therapeutics (GLUE), and AxoGen (AXGN). These companies are all part of the "medical" sector.
Sanara MedTech (NASDAQ:SMTI) and Codexis (NASDAQ:CDXS) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their dividends, media sentiment, risk, institutional ownership, analyst recommendations, community ranking, earnings, valuation and profitability.
8.1% of Sanara MedTech shares are held by institutional investors. Comparatively, 78.5% of Codexis shares are held by institutional investors. 54.1% of Sanara MedTech shares are held by company insiders. Comparatively, 6.3% of Codexis shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Codexis received 326 more outperform votes than Sanara MedTech when rated by MarketBeat users. Likewise, 61.21% of users gave Codexis an outperform vote while only 54.55% of users gave Sanara MedTech an outperform vote.
Sanara MedTech has a net margin of -7.19% compared to Sanara MedTech's net margin of -87.73%. Codexis' return on equity of -11.33% beat Sanara MedTech's return on equity.
In the previous week, Sanara MedTech had 3 more articles in the media than Codexis. MarketBeat recorded 6 mentions for Sanara MedTech and 3 mentions for Codexis. Sanara MedTech's average media sentiment score of 0.20 beat Codexis' score of -0.11 indicating that Codexis is being referred to more favorably in the news media.
Sanara MedTech has a beta of 1.67, indicating that its share price is 67% more volatile than the S&P 500. Comparatively, Codexis has a beta of 2.04, indicating that its share price is 104% more volatile than the S&P 500.
Sanara MedTech has higher earnings, but lower revenue than Codexis. Sanara MedTech is trading at a lower price-to-earnings ratio than Codexis, indicating that it is currently the more affordable of the two stocks.
Sanara MedTech presently has a consensus price target of $44.00, suggesting a potential upside of 39.73%. Codexis has a consensus price target of $6.80, suggesting a potential upside of 109.88%. Given Sanara MedTech's higher probable upside, analysts clearly believe Codexis is more favorable than Sanara MedTech.
Summary
Sanara MedTech and Codexis tied by winning 9 of the 18 factors compared between the two stocks.
Get Codexis News Delivered to You Automatically
Sign up to receive the latest news and ratings for CDXS and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CDXS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
